Pivotal Phase 3 Study Shows Ralinepag Achieved 55% Reduction in Clinical Worsening for PAH Patients

summarizeSummary

United Therapeutics announced highly positive Phase 3 ADVANCE OUTCOMES study results for ralinepag, demonstrating a significant 55% reduction in the risk of clinical worsening in pulmonary arterial hypertension (PAH) patients.

check_boxKey Events

• Pivotal Phase 3 Study Met Primary Endpoint

  The ADVANCE OUTCOMES clinical study of ralinepag achieved its primary endpoint, reducing the risk of a clinical worsening event by 55% compared to placebo in patients with pulmonary arterial hypertension (PAH) (p<0.0001).

• Significant Improvements in Secondary Endpoints

  Ralinepag demonstrated statistically significant improvements in important secondary endpoints, including six-minute walk distance (6MWD) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), increasing the odds of clinical improvement by 47%.

• Favorable Safety Profile

  Treatment with ralinepag was well-tolerated, with a safety profile consistent with known prostacyclin-related adverse events and no new safety signals observed.

• NDA Submission Planned for H2 2026

  United Therapeutics intends to submit a New Drug Application (NDA) for ralinepag to the U.S. Food and Drug Administration (FDA) by the second half of 2026.

auto_awesomeAnalysis

United Therapeutics announced highly positive Phase 3 clinical trial results for ralinepag, a drug candidate for pulmonary arterial hypertension (PAH). The significant 55% reduction in clinical worsening events, coupled with improvements in key secondary endpoints, de-risks this major pipeline asset and positions ralinepag as a potential game-changer in PAH treatment. The company's plan to submit a New Drug Application (NDA) to the FDA by the second half of 2026 indicates a clear and accelerated path towards commercialization, which could substantially impact future revenue and market share in the PAH therapeutic area.